GCIA
AMED

Gabelli & Co Investment Advisers’s Amedisys AMED Stock Holding History

Gabelli & Co Investment Advisers’s Portfolio AMED Stock Details AMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-224,443
Closed -$22.1M – 276
2025
Q2 		$22.1M Buy
224,443
+26,948
+14% +$2.55M 3.39% 5
2025
Q1 		$18.3M Buy
197,495
+5,050
+3% +$466K 2.77% 5
2024
Q4 		$17.5M Sell
192,445
-8,236
-4% -$756K 2.98% 7
2024
Q3 		$19.4M Sell
200,681
-3,692
-2% -$360K 3.3% 4
2024
Q2 		$18.8M Buy
204,373
+7,550
+4% +$701K 3.13% 4
2024
Q1 		$18.1M Sell
196,823
-4,700
-2% -$440K 3.16% 6
2023
Q4 		$19.2M Buy
201,523
+38,550
+24% +$3.6M 3.59% 6
2023
Q3 		$15.2M Buy
162,973
+130,723
+405% +$12.1M 2.48% 12
2023
Q2 		$2.95M Buy
+32,250
New +$2.65M 0.49% 45

Other funds holding AMED

Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MCI
MRP Capital Investments Alpharetta, Georgia $115M AUM 48.08% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Gabelli & Co Investment Advisers's AMED Position: Q3 2025 in Review

Gabelli & Co Investment Advisers sold out of Amedisys (AMED) in Q3 2025, closing a stake of 224,443 shares — an estimated $22.1M sold.

Gabelli & Co Investment Advisers first reported a position in AMED in Q2 2023 and held it in 9 quarters. The position peaked at $22.1M in Q2 2025. 4 funds tracked by Wall St. Rank hold AMED as of Q3 2025.

  • Gabelli & Co Investment Advisers reported no remaining Amedisys position as of Q3 2025 after selling out during the quarter.
  • Gabelli & Co Investment Advisers sold 224,443 Amedisys shares in Q3 2025, an estimated $22.1M.
  • Gabelli & Co Investment Advisers first reported a position in Amedisys in Q2 2023 and held it in 9 quarters.
  • Gabelli & Co Investment Advisers's Amedisys position peaked at $22.1M in Q2 2025.
  • 4 funds tracked by Wall St. Rank held Amedisys as of Q3 2025.

Based on Gabelli & Co Investment Advisers's 13F filing for Q3 2025, filed 12 Nov 2025.